When only considering the most common BC subtype of HR+/HER2- (n = 48), per-sample detection accuracy was 86.7% (95% CI 76–93.8%) with 78% SE (95% CI: 61.5–89.2%) at 89% SP (95% CI: 69.9–97.6%). The gene discussed is ERBB2; the disease is breast cancer.